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The real-time quaking-induced conversion (RT-QuIC) assay is a highly reproducible and
robust methodology exhibiting an excellent pre-mortem diagnostic accuracy for prion
diseases. However, the protocols might be time-consuming and improvement of the
detection technology is needed. In the present study, we investigated the influence of a
pre-analytical cerebrospinal fluid (CSF) treatment with proteinase K (PK) on the kinetic of
the RT-QuIC signal response. For this purpose, we added PK at different concentrations
in RT-QuIC reactions seeded with Creutzfeldt–Jakob disease (sCJD) CSF. We observed
that a mild pre-analytical PK treatment of CSF samples resulted in an increased
seeding efficiency of the RT-QuIC reaction. Quantitative seeding parameters, such as
a higher area under the curve (AUC) value or a shorter lag phase indicated a higher
conversion efficiency after treatment. The diagnostic accuracy resulting from 2 µg/ml
PK treatment was analyzed in a retrospective study, where we obtained a sensitivity of
89%. Additionally, we analyzed the agreement with the previously established standard
RT-QuIC protocol without PK treatment in a prospective study. Here, we found an
overall agreement of 94% to 96%. A Cohen’s kappa of 0.9036 (95% CI: 0.8114–
0.9958) indicates an almost perfect agreement between both protocols. In conclusion,
the outcome of our study can be used for a further optimization of the RT-QuIC assay
in particular for a reduction of the testing time.
Keywords: cerebrospinal fluid, Creutzfeldt-Jakob disease, diagnostic test, prion protein, real-time quaking-
induced conversion
INTRODUCTION
The pre-mortal diagnostic criteria of Creutzfeldt–Jakob disease (sCJD) include clinical
examinations combined with magnetic resonance imaging (MRI) of the brain,
electroencephalography (EEG), and laboratory analysis of cerebrospinal fluid (CSF; WHO, 1998,
2003; Zerr et al., 2009). Surrogate biomarkers such as 14-3-3, tau, alpha synuclein, etc. were applied
for pre-mortem diagnosis (Zerr et al., 1998; Llorens et al., 2016, 2017; Schmitz et al., 2016c,d,
2019). A major innovation in prion disease diagnostic was the development of in vitro protein
misfolding cyclic amplification (PMCA) assays. These include the PMCA (Saborio et al., 2001),
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the amyloid seeding assay (ASTA; Colby et al., 2007), the
quaking-induced conversion (QuIC; Atarashi et al., 2008), and
the real-time quaking-induced conversion (RT-QuIC; Atarashi
et al., 2011; McGuire et al., 2012; Orru et al., 2014; Schmitz
et al., 2016a,b). Atarashi et al. (2011) firstly used the RT-QuIC to
amplify minuscule amounts of a PrPSc seed in CSF from patients
with prion disease. Afterward, a high specificity of approximately
100%, robustness, and high reproducibility of the RT-QuIC had
been demonstrated by several groups (McGuire et al., 2012, 2016;
Sano et al., 2013; Cramm et al., 2015, 2016). The sensitivity of
the RT-QuIC depends on the kind of prion disease (Sano et al.,
2013; Cramm et al., 2015); for sCJD, it varies between 80% and
95%. Other confounding factors are the composition of the study
cohort or the type of recombinant PrPC (hamster, hamster–sheep,
human, bank vole, etc.; Orru et al., 2015; Candelise et al., 2017).
Recently, a suggestion has been made to amend the criteria by
adding the PrPSc detection by RT-QuIC (Hermann et al., 2018).
Therefore, a further optimization of the RT-QuIC by reducing the
average testing time of 80 h would be beneficial.
In the present study, we analyzed the influence of a mild pre-
analytical proteinase K (PK) treatment of CSF samples (sCJD
and controls) on the PrP conversion efficiency in the RT-QuIC
as defined by quantitative seeding parameters, such as the lag
phase or the area under the curve (AUC). After selection of a PK
concentration, we performed a retrospective study to define the
sensitivity and a prospective study to compare the accordance of
the RT-QuIC with and without pre-analytical PK treatment.
MATERIALS AND METHODS
Ethics Statement
The studies involving human CSF samples were reviewed and
approved by the local Ethics Committee of the University
Medicine Göttingen, Von Siebold-Str. 37075 Göttingen,
No. 24/8/12. All samples were analyzed blinded for at
least personal data.
Patients
We performed a retrospective study including 65 sCJD patients
[35 patients with codon 129 homozygous methionine genotype
(MM), 15 heterozygous MV, and 15 VV cases] as well as 20
control subjects without prion disease. All sCJD cases were
diagnosed as probable cases according to diagnostic consensus
criteria; 20 were confirmed by autopsy (WHO, 1998, 2003; Zerr
et al., 2009). From them, we used four sCJD MM cases for
studying the influence of PK incubation and deactivation steps
on RT-QuIC signal response.
The control group included patients either healthy or with
clinically defined alternative diagnosis such as Alzheimer’s
disease, alpha synucleinopathies, or psychiatric disorders
(psychosis, bipolar disorder, and schizophrenia). Additionally,
we included a prospective cohort that consisted of 35 RT-QuIC
positive cases (suspected sCJD cases) and 51 cases exhibiting a
negative RT-QuIC seeding response (suspected controls). These
samples were collected during diagnostic routine without any
further characterization.
RT-QuIC Analysis
We conducted the RT-QuIC analysis according to an established
protocol (Schmitz et al., 2016b, 2018). Each sample was run
in triplicates. Briefly, 85 µl of RT-QuIC buffer [162 mM
phosphate buffer (pH 6.9), 170 mM sodium chloride, 1 mM
ethylenediaminetetraacetic acid (EDTA), 10 µM Thioflavin-T
(Th-T), and 0.1 mg/ml recPrP] was seeded with 15 µl of CSF
(total volume of 100 µl). For RT-QuIC analysis, we used the
BMG OPTIMA FLUOStar plate reader. Reactions were run at
42◦C for 80 h with intermittent shaking cycles [1-min double
orbital shaking at the highest speed (600 rpm)] followed by 1-min
incubation. Every 30 min, fluorescence was measured at 450-nm
excitation and 480-nm emission.
Pre-analytical PK Treatment
Cerebrospinal fluid samples were subjected to a mild pre-
analytical treatment with PK in a range of 0–6 µg/ml. After
adding PK, samples were incubated for 30 min at 37◦C.
Subsequently, PK was deactivated by heating at 65◦C for 30 min.
Coomassie Brilliant Blue Staining
Acrylamide gels (12%) were fixed in a solution containing 50%
methanol and 10% glacial acetic acid for 1 h. After 1 h, solution
was exchanged. Staining with 1% Coomassie brilliant blue R-250,
50% methanol, and 10% glacial acetic occurred for 20 min with
gentle agitation. Destaining in 40% methanol and 10% glacial
acetic acid solution was carried out until the gel background was
fully transparent destained. Finally, gels were stored at RT in 5%
glacial acetic acid solution.
Statistical Analysis
Agreement between the standard and the modified protocol was
measured with the Cohen’s kappa statistics, available in the vcd R
package (Meyer et al., 2020). Then, measures of seeding efficiency
were calculated for each individual sample defined by relative
area under the curve (rel. AUC) and lag phase (time to 50% signal
increase). Multiple comparisons data were analyzed by one-way
ANOVA followed by Dunn’s Post hoc test. Two groups (normally
distributed) were compared using the Student’s t test, while
for non-normally distributed values, we considered the Mann–
Whitney U test as appropriate. All analyses were conducted by
using GraphPad Prism 8.
RESULTS
Influence of Serial Pre-analytical PK
Treatments on the RT-QuIC Seeding
Response
We performed a mild pre-analytical treatment of CSF samples
with PK (2 µg/ml). After adding PK, samples were incubated for
30 min at 37◦C. Subsequently, PK was deactivated by heating at
65◦C for 30 min.
The incubation step for 30 min at RT or at 37◦C alone or in
combination with the incubation of 30 min at 65◦C (without PK)
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FIGURE 1 | Influence of PK incubation and deactivation steps on the RT-QuIC signal response. (A,B) All incubation and deactivation steps without PK (addition of
water instead of PK) had no effect on the seeding kinetic and the AUC values in sCJD (MM; n = 4) seeded RT-QuIC reactions. (C,D) PK treatment (2 mg/ml) requires
a deactivation step (30 min at 65◦C); otherwise, no seeding reaction is observable when incubating with PK at room temperature (RT) or at 37◦C. (E,F) In
control-seeded reactions (n = 4), neither the incubation of 30 min at RT or at 37◦C nor the deactivation for 30 min at 65◦C exhibited a significant influence on the
signal response independently from PK treatment. p values: <0.001 as extremely significant (***).
exhibited a non-significant effect on signal response compared to
untreated reactions (Figures 1A,B).
In PK-treated reactions, the deactivation step is required;
otherwise, all sCJD (MM) seeded reactions showed a negative
seeding response comparable to controls (Figures 1C,D). In
control seeded reactions, none of the conditions had changed the
seeding kinetics (Figures 1E,F).
Subsequently, 20 well-characterized CSF samples from sCJD
(MM) patients and 20 controls without prion disease were
treated with different PK concentrations (0–6 µg/ml). After PK
treatment, samples were subjected to RT-QuIC analysis using the
standard protocol (Cramm et al., 2016; Schmitz et al., 2016b,
2018), which included recombinant hamster–sheep as substrate.
The signal-kinetic in the RT-QuIC reaction was measured in
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FIGURE 2 | Influence of different amounts of PK on the RT-QuIC seeding response. (A,B) RT-QuIC reactions seeded either with sCJD MM or with control CSF were
treated with different amounts of PK (0–6 µg/ml). The kinetics of positive RT-QuIC signaling responses indicated that treatment with PK influences the conversion
efficiency of PrP in comparison to untreated reactions. (C) Accuracy of the RT-QuIC before and after PK treatment suggested a pre-treatment with 2 µg/ml PK as
most suitable for a reliable diagnostic. For simplification, we displayed the means of all positive sCJD and negative control seeded reactions per group at each point
in time and not the false-positive or -negative reactions.
dependency from the PK concentration (0–6 µg/ml). It indicated
a significant increase of the conversion efficiency of reactions,
seeded with sCJD CSF after PK treatment (Figures 2A,B). To
define the optimal assay conditions for the sCJD diagnosis,
we validated the correctly classified sCJD and control cases.
Interestingly, the pre-analytical PK treatment of CSF samples
in a concentration of 2 µg/ml revealed the best diagnostic
accuracy; 19/20 sCJD cases and 0/20 control cases showed over a
duration of 40 h testing time a positive RT-QuIC signal response
(Figure 2C). The use of higher PK amounts and longer testing
times may result in false-positive RT-QuIC reactions (Figure 2C).
Pre-analytical PK Treatment (2 µg/ml)
Significantly Reduced the Lag Phase and
the Testing Time of the RT-QuIC
The impact of a pre-analytical CSF treatment with 2 µg/ml PK on
the total protein amount and the quantitative seeding parameters
(such as lag phase and AUC) was now analyzed more in detail.
At first, we compared the total protein amount in sCJD
MM CSF samples before and after PK treatment (2 µg/ml)
by gel electrophoresis followed by Coomassie Brilliant Blue
staining. Quantification of band intensities occurred by Image
Lab software. Interestingly, we observed total protein amounts
up to 50% decreased after PK treatment (Supplementary
Figures 1A,B).
Next, we calculated quantitative seeding parameters of
untreated in comparison to PK (2 µg/ml)-treated RT-QuIC
reactions seeded with sCJD MM CSF. The obtained data
indicated that RT-QuIC reactions pre-analytically exposed to PK
revealed a significantly shorter lag phase, which decreased from
more than 30 h (untreated) to 6–9 h on average as well as an
increased AUC value after PK treatment (Figures 3A–C), while
controls remained on a baseline level (Figure 3D).
Determination of the Sensitivity After PK
Treatment in a Retrospective Study
The sensitivity of RT-QuIC after pre-analytical treatment
with PK was analyzed in a retrospective study. The cohort
consisted of 65 sCJD patients (35 MM, 15 MV, and 15 VV).
After pre-analytical exposure to 2 µg/ml PK, samples were
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FIGURE 3 | Optimization of the CSF RT-QuIC. (A) RT-QuIC reactions terminated at 40 h and seeded with sCJD MM CSF (n = 20) were treated with 2 µg/ml of PK,
which increased the conversion efficiency of PrP significantly as indicated by a shorter lag phase (B) and a higher relative area under the curve (AUC) value (C).
Non-prion disease controls (n = 20) remained negative (D). (E) In a retrospective study, we analyzed the sensitivity of the RT-QuIC after PK (2 µg/ml) treatment in
different sCJD codon 129 MV genotypes showing an average sensitivity of 89% for all sCJD codon 129 MV genotypes. RT-QuIC responses were measured in rfu
over a period of 40 h. Displayed are means ± SEM (standard error of the mean) at each point in time. p values: <0.001 as extremely significant (***).
analyzed via RT-QuIC for 40 h. The sensitivities varied between
different sCJD codon 129 MV genotypes between 87% and
91%, while the average sensitivity for all sCJD genotype was
89% (Figure 3E).
Examination of the Agreement Between
Optimized and Standard RT-QuIC
To determine the analytical agreement of the optimized RT-QuIC
(with PK 2 µg/ml) and the standard RT-QuIC, a prospective
study on a patient cohort consisting of 35 samples with a positive
RT-QuIC response as well as 51 samples exhibiting a negative
standard RT-QuIC response was performed. PK-treated and
untreated samples were analyzed in parallel on the same plate.
Interestingly, we obtained an agreement of 94% for the RT-
QuIC positively classified cases and 96% for all CSF samples
exhibiting a negative RT-QuIC signal response (Table 1). In
addition, we calculated the Cohen’s kappa value to determine
the agreement between the standard and the optimized RT-QuIC
protocol. Interestingly, we obtained a value of 0.9036 (95% CI:
0.8114–0.9958), which indicates an almost perfect agreement
between both protocols.
DISCUSSION
Until now, several in vitro protein misfolding amplification
systems, such as the RT-QuIC, have been established
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TABLE 1 | In a prospective study, we analyzed the agreement of untreated
(standard) and PK (2 µg/ml)-treated (optimized) RT-QuIC reactions.




RT-QuIC positive reactions 35 33 94%
RT-QuIC negative reactions 51 49 96%
We selected CSF samples with positive or negative signal response in the standard
RT-QuIC and analyzed them in parallel in the optimized RT-QuIC.
providing relevant improvements in prion disease diagnostics
and prion research (Atarashi et al., 2011; McGuire et al.,
2012; Sano et al., 2013; Cramm et al., 2015, 2016). The
standard diagnostic RT-QuIC protocol for the analysis of
sCJD CSF (with recombinant hamster–sheep PrPC as a
substrate) exhibited a total assay duration for testing of
80 h (Cramm et al., 2015, 2016; Schmitz et al., 2016a,b,
2018). The lag phase of a positive RT-QuIC reaction lasts
30–40 h in average with accuracy between 80 and 85%
and a specificity of almost 100% (Cramm et al., 2016).
In the present study, we intend to modify the RT-QuIC
standard protocol to reduce the lag phase and the testing
time of the RT-QuIC.
Optimization of sCJD RT-QuIC by a
Pre-analytical PK Treatment
In an initial study, we included a mild PK treatment of CSF
in the pre-analytical protocol. Afterward, CSF samples were
subjected to the standard RT-QuIC analysis (Cramm et al.,
2016; Schmitz et al., 2016b, 2018). To elucidate the optimal
amount of PK, we performed a serial dilution from 0 to
6 µg/ml of PK. All PK concentrations ≥2 µg/ml reduced the
lag phase significantly. However, the diagnostic accuracy of
the optimized RT-QuIC depended on the amount of PK. The
usage of ≥3 µg/ml of PK resulted in a significant decrease
of the specificity by creating false-positive RT-QuIC signals,
as revealed by control RT-QuIC reactions (CSF without prion
disease). A 2 µg/ml PK treatment provided the best diagnostic
accuracy and allowed a reduction of the testing time from 80
to 40 h. Under these conditions, the PrP conversion process
is accelerated, as indicated by a reduced lag phase and an
increase of AUC values compared to the standard protocol
without PK treatment. A potential reason may be that PK
treatment resulted in a decrease of total protein amounts of
more than 50%. Lower protein levels may affect the PrPC–
PrPRes interaction in the RT-QuIC, which most likely promotes
the conversion efficiency. Alternatively, it could be that PK
partially digests external parts of PrPRes species. This way, inner
beta strands may become more exposed, displaying a higher
seeding capacity.
To examine the application to all sCJD codon 129 MV
genotypes and define the diagnostic sensitivity, a retrospective
study was performed by analyzing 65 confirmed sCJD cases.
Here, we obtained an average sensitivity for all genotypes of 89%.
This is an increase compared to the standard RT-QuIC protocol
(Cramm et al., 2016; Schmitz et al., 2016b, 2018), whereas the
number of samples was lower.
In addition, we investigated the agreement of the new
protocol (with PK) to the previous standard protocol in a
prospective study. The accordance between both protocols varied
between 94 and 96% with a Cohen’s kappa of 0.9036 (95% CI:
0.8114–0.9958), which indicates an almost perfect agreement
between both protocols. For four CSF samples, where we do
not have any follow-up information, both protocols disagreed.
One explanation may be an increase of sensitivity of the RT-
QuIC after PK treatment. However, to finally elucidate this
issue, a retrospective study on a higher number of well-
characterized samples (e.g., >200 sCJD samples, consisting of
typical and atypical sCJD cases as well as >100 neurological
controls) is recommended.
Besides the standard or first generations of the RT-QuIC, a
few studies successfully applied a so termed second generation
of the RT-QuIC assay. In the second generation of the RT-
QuIC, a truncated Syrian hamster recombinant PrP substrate
(amino acids 90–231) and some modifications [incubations at
55◦C instead of 42◦C, and the addition of 0.002% sodium dodecyl
sulfate (SDS)] of the standard RT-QuIC protocol have been
used (Foutz et al., 2017; Franceschini et al., 2017; Groveman
et al., 2017). In contrast to the full-length recombinant PrP
substrate, the use of truncated recombinant PrP as a substrate
contributed to an acceleration of the RT-QuIC seeding response
and an increase of the conversion efficiency. The lag phase
(less than 20 h) and the detection times (2-day reduction in
average detection time) were significantly reduced in the second
generation of the RT-QuIC (Foutz et al., 2017; Franceschini
et al., 2017; Groveman et al., 2017), which is comparable to the
optimized protocol with PK treatment. Moreover, the sensitivity
of the RT-QuIC could be increased (up 94%, 113 CJD cases
were tested) without loss of specificity (100%; Foutz et al., 2017;
Franceschini et al., 2017; Groveman et al., 2017; Thompson and
Mead, 2019).
In summary, our study provides an alternative to the
originally as second generation described RT-QuIC for a further
optimization of this test. The pre-analytical treatment of CSF with
PK helps to reduce the testing time by increasing the conversion
efficiency indicated by a shorter lag phase, higher AUC values,
and an increase of the sensitivity.
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Supplementary Figure 1 | Decrease of total protein amounts after treatment with
PK 2 µg/ml (A) CSF samples from sCJD MM patients either treated with PK or
untreated were stained with Coomassie brilliant blue. (B) Densitometric analysis
via Image Lab indicated a decrease of total protein amount after
treatment with PK.
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